Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 12 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 11578135

    Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  2. US 11571482

    Human antibodies to S. aureus Hemolysin A toxin

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 7, 2023 · Expires Feb 2, 2043

    granted
  3. US 11571636

    Methods for quantitating individual antibodies from a mixture

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 7, 2023 · Expires Feb 2, 2043

    granted
  4. US 11559576

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted
  5. US 11559564

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted
  6. US 11559489

    Tuning of release kinetics in hydrogels

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted
  7. US 11547101

    Non-human animals having a disruption in a C9ORF72 locus

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  8. US 11548932

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  9. US 11548947

    Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  10. US 11542326

    Anti-IL-25 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  11. US 11542317

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  12. US 11535663

    Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted
  13. US 11535675

    Antigen-binding proteins that antagonize leptin receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted
  14. US 11530255

    Human antibodies to Ebola virus glycoprotein

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted
  15. US 11525629

    Target residual moisture content for lyophilized drug product

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted
  16. US 11525001

    Anti-CD8 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted
  17. US 11518804

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  18. US 11519020

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  19. US 11511001

    Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  20. US 11512309

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  21. US 11504390

    Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  22. US 11505600

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  23. US 11505594

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  24. US 11505593

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted